Scarica l'app Stockscreener
5.34
5.12%
0.26
Pre-mercato:
5.19
-0.15
-2.81%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Cumberland Pharmaceuticals Inc Borsa (CPIX) Ultime notizie
Financial Survey: Cumberland Pharmaceuticals (NASDAQ:CPIX) versus Skye Bioscience (NASDAQ:SKYE) - Defense World
Adversity is less terrifying than hope: Cumberland Pharmaceuticals Inc (CPIX) - SETE News
Cumberland Pharma (CPIX) Achieves Key Milestone, Stock Jumps - Stocks Telegraph
Cumberland Pharmaceuticals sees nearly 50 million shares trade - Nashville Post
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD - Yahoo Finance
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD heart disease - Clinical Trials Arena
Pharma Stock Soars On Phase 2 Announcement - The Globe and Mail
Cumberland Pharmaceuticals stock soars - Nashville Post
Uncovering the Potential of Cumberland Pharmaceuticals Inc (CPIX) Stock - The InvestChronicle
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease - Benzinga
Stock market news: Nuvve Holding +47.92%, Flexsteel Industries +28.15% among top gainers during mid day trading - Business Upturn
Cumberland Pharmaceuticals Inc (CPIX) Stock Price and Analyst Predictions - The News Heater
Is CPIX’s price to cash per share ratio a concern for investors? - US Post News
Cumberland reports progress in DMD heart disease trial - MSN
Cumberland's Duchenne drug improves blood flow from heart in phase 2 trial - Fierce Biotech
Cumberland Vaults on DMD Test Results - Baystreet.ca
Cumberland Pharmaceuticals Announces Phase 2 Fight Dmd Trial Results For Duchenne Muscular Dystrophy Heart Disease - Marketscreener.com
Cumberland's DMD Heart Disease Drug Shows Breakthrough 5.4% LVEF Improvement in Phase 2 | CPIX Stock News - StockTitan
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Hepatorenal Syndrome Treatment Market: Increasing Demand, Market Size, and Foreseen Trends for 2024-2029 - openPR
Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs - openPR
StockNews.com Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX) - Defense World
Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
SAP (SAP) Expected to Announce Earnings on Tuesday - Defense World
Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire
3 US Penny Stocks With Market Caps Over $30M - Yahoo Finance
Dilated Cardiomyopathy Pipeline Overview 2024: FDA Approvals and Key Developments | Vericel Corporation, AstraZeneca, Pfizer, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics - The Globe and Mail
Improved Revenues Required Before Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Stock's 26% Jump Looks Justified - Simply Wall St
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight - GlobeNewswire Inc.
CPIX stock touches 52-week high at $3.09 amid market rally - Investing.com
scPharmaceuticals Provides Preliminary Financial Results for Fourth Quarter and Full Year 2024On January 10, 2025, scPharmaceuticals Inc. (NASDAQ: SCPH) released an 8-K filing containing preliminary unaudited financial information for the quarter and - Defense World
Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated at StockNews.com - Defense World
Cumberland Pharmaceuticals director Krogulski buys $8,209 in stock - Investing.com India
Cumberland Pharmaceuticals director James Jones acquires $1,317 in stock By Investing.com - Investing.com Nigeria
Cumberland Pharmaceuticals CEO AJ Kazimi purchases $1317 in stock By Investing.com - Investing.com Nigeria
Cumberland Pharmaceuticals director Krogulski buys $8,209 in stock By Investing.com - Investing.com Canada
Cumberland Pharmaceuticals director Caroline Young acquires $256 in stock By Investing.com - Investing.com Canada
Cumberland Pharmaceuticals director James Jones acquires $1,317 in stock - Investing.com India
Cumberland Pharmaceuticals CEO AJ Kazimi purchases $1317 in stock - Investing.com
Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by StockNews.com - Defense World
Athira Pharma (NASDAQ:ATHA) Stock Quotes, Forecast and News Summary - Benzinga
StockNews.com Begins Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX) - Defense World
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above 200-Day Moving Average – Here’s Why - Defense World
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
3 Penny Stocks to Watch Now, 12/12/24 - TipRanks
3 Promising Penny Stocks With Market Caps Under $2B In US - Simply Wall St
FDA APPROVES ACETADOTE® sNDA - Citizentribune
Cumberland Pharmaceuticals stock pops - Nashville Post
Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change - GuruFocus.com
Stock Skyrockets! Discover What’s Fueling This Company’s Massive Surge. - elblog.pl
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings - Benzinga
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday? - Benzinga
Cumberland Pharma Stock Hits 16-Month High After FDA Approves Liver Drug Regimen: Retail’s Thrilled - MSN
Cumberland (CPIX) Celebrates FDA Nod With Market Rally - Stocks Telegraph
FDA Approves Simplified Dosing For Cumberland's Acetadote - Contract Pharma
CPIX stock touches 52-week high at $2.92 amid market fluctuations - Investing.com
0.25%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):